The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside
(NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving
infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or
recurrent platinum-resistant ovarian, endometrial, peritoneal, or fallopian tube cancer.
Intervention
Nicotinamide Riboside
Condition
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer
Investigators
Donna L Hammond, PhD, Alexandra Thomas, MD